Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 531Squamous Cell Carcinoma of Head and Neck 273Head and Neck Neoplasms 252Lung Neoplasms 238Uterine Cervical Neoplasms 176Stomach Neoplasms 168Esophageal Neoplasms 160Nasopharyngeal Carcinoma 123Urinary Bladder Neoplasms 116Esophageal Squamous Cell Carcinoma 114Neoplasms 113Small Cell Lung Carcinoma 103Breast Neoplasms 92Ovarian Neoplasms 89Neoplasm Metastasis 89Carcinoma, Squamous Cell 76Cholangiocarcinoma 75Pancreatic Neoplasms 71Biliary Tract Neoplasms 69Mesothelioma, Malignant 57Oropharyngeal Neoplasms 56Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 47Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 45Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Gallbladder Neoplasms 38

Interventions

eribulin 3Vinorelbine 2Paclitaxel 2Epirubicin 2Doxorubicin 2Cyclophosphamide 2trastuzumab deruxtecan 1tislelizumab 1taxane 1sacituzumab govitecan 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1camrelizumab 1anlotinib 1Taxes 1Precision Medicine 1Gemcitabine 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1Anthracyclines 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2-negative Breast Cancer × Cisplatin × Clear all
NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Peking University First Hospital

Phase 2 Unknown
30 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡